Multidimensional endotyping using nasal proteomics predicts molecular phenotypes in the asthmatic airways - 04/01/23
, Mohamed H. Shamji, PhD, FAAAAI c, d, ⁎, ∗
, Nazanin Zounemat Kermani, PhD c, e, Giulia Vecchi, PhD f, Alberto Favaro, PhD f, Janice A. Layhadi, PhD c, d, Anja Heider, PhD g, Didem Sanver Akbas, PhD c, d, Paulina Filipaviciute, MSc c, d, Lily Y.D. Wu, BSc c, d, Catalina Cojanu, MD, PhD a, b, Alexandru Laculiceanu, MD a, b, Cezmi A. Akdis, MD, PhD g, h, ‡, Ian M. Adcock, PhD c, d, ‡Abstract |
Background |
Unsupervised clustering of biomarkers derived from noninvasive samples such as nasal fluid is less evaluated as a tool for describing asthma endotypes.
Objective |
We sought to evaluate whether protein expression in nasal fluid would identify distinct clusters of patients with asthma with specific lower airway molecular phenotypes.
Methods |
Unsupervised clustering of 168 nasal inflammatory and immune proteins and Shapley values was used to stratify 43 patients with severe asthma (endotype of noneosinophilic asthma) using a 2 “modeling blocks” machine learning approach. This algorithm was also applied to nasal brushings transcriptomics from U-BIOPRED (Unbiased Biomarkers for the Prediction of Respiratory Diseases Outcomes). Feature reduction and functional gene analysis were used to compare proteomic and transcriptomic clusters. Gene set variation analysis provided enrichment scores of the endotype of noneosinophilic asthma protein signature within U-BIOPRED sputum and blood.
Results |
The nasal protein machine learning model identified 2 severe asthma endotypes, which were replicated in U-BIOPRED nasal transcriptomics. Cluster 1 patients had significant airway obstruction, small airways disease, air trapping, decreased diffusing capacity, and increased oxidative stress, although only 4 of 18 were current smokers. Shapley identified 20 cluster-defining proteins. Forty-one proteins were significantly higher in cluster 1. Pathways associated with proteomic and transcriptomic clusters were linked to TH1, TH2, neutrophil, Janus kinase-signal transducer and activator of transcription, TLR, and infection activation. Gene set variation analysis of the nasal protein and gene signatures were enriched in subjects with sputum neutrophilic/mixed granulocytic asthma and in subjects with a molecular phenotype found in sputum neutrophil-high subjects.
Conclusions |
Protein or gene analysis may indicate molecular phenotypes within the asthmatic lower airway and provide a simple, noninvasive test for non–type 2 immune response asthma that is currently unavailable.
Le texte complet de cet article est disponible en PDF.Graphical abstract |
Key words : Severe asthma, T2 asthma, biomarkers, nasal proteomics, machine learning, trascriptome-associated cluster, endotypes
Abbreviations used : AUC, ENDANA, ES, GINA, ML, ROC, T2, TAC, U-BIOPRED
Plan
| This study was funded, in part, by the PN-II-RU-TE-2014-4 programme, the UK Medical Research Council (MRC) (grant nos. MR/T010371/1 and MR/M016579/1), and the National Institute for Health and Care Research (NIHR) Imperial Biomedical Research Centre (BRC). I.M.A. is supported by the Engineering and Physical Sciences Research Council (EPSRC; grant nos. EP/T003189/1 and EP/V052462/1), the UK MRC (grant nos. MR/T010371/1 and MR/M016579/1), and the Wellcome Trust (grant no. 208340/Z/17/Z). N.Z.K. is supported by the UK MRC (MR/T010371/1 and MR/M016579/1). The clinical trial performed by Ioana Agache was funded through the PN-II-RU-TE-2014-4-2303 ENDANA project. All aspects of the research performed at Imperial College London were funded by the BRC and Imperial College Trust. Unbiased Biomarkers for the Prediction of Respiratory Diseases Outcomes was supported by an Innovative Medicines Initiative Joint Undertaking (no. 115010), resources from the European Union’s Seventh Framework Programme (FP7/2007-2013), and European Federation of Pharmaceutical Industries and Associations (EFPIA) companies’ in-kind contribution (www.imi.europa.eu). |
|
| Disclosure of potential conflict of interest: I. Agache reports research grants from the Romanian Ministry of Education and Research (UEFISCDI) and Actelion/Idorsia and lectures fees from AstraZeneca, Novartis, Chiesi, Sanofi, Mylan, and ALK. M. H. Shamji reports research grants from Immune Tolerance Network, Medical Research Council, Allergy Therapeutics, LETI Laboratorios, and Rovolo Biotherapeutics and lecture fees from Allergy Therapeutics and Leti Laboratorios. C. A. Akdis received research grants from Novartis, Astra Zeneca (AZ), GlaxoSmithKline (GSK), Idorsia, Scibase, EU Horizons Cure, and Swiss National Science Foundation and takes advisory roles in Scibase, Regeneron/Sanofi, and Novartis. I. M. Adcock is supported by the EPSRC (EP/T003189/1 and EP/V052462/1), the UK Medical Research Council (MR/T010371/1 and MR/M016579/1), and the Wellcome Trust (208340/Z/17/Z) and reports investigator-led research grants from GSK and lectures fees from AZ, GSK, Kinexis, and Eurodrug. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 151 - N° 1
P. 128-137 - janvier 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
